Blase Polite to United States
This is a "connection" page, showing publications Blase Polite has written about United States.
Connection Strength
1.354
-
Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will. Cancer J. 2020 Jul/Aug; 26(4):304-310.
Score: 0.074
-
Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer. JAMA. 2019 May 07; 321(17):1663-1664.
Score: 0.068
-
State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 04; 15(4):163-165.
Score: 0.067
-
A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399.
Score: 0.064
-
Impact on Oncology Practices of Including Drug Costs in Bundled Payments. J Oncol Pract. 2018 05; 14(5):e259-e268.
Score: 0.063
-
Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations. Cancer. 2018 06 15; 124(12):2578-2587.
Score: 0.063
-
Blase Polite on How Disparities Research Must Move Into an Era of Action. Oncology (Williston Park). 2017 10 15; 31(10):709-10, 717.
Score: 0.061
-
Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol. 2017 09 10; 35(26):3075-3082.
Score: 0.060
-
Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. CA Cancer J Clin. 2017 09; 67(5):353-361.
Score: 0.060
-
Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Cancer Res. 2017 09 01; 77(17):4548-4555.
Score: 0.060
-
A Pathway Through the Bundle Jungle. J Oncol Pract. 2016 06; 12(6):504-9.
Score: 0.055
-
Oncology Pathways-Preventing a Good Idea From Going Bad. JAMA Oncol. 2016 Mar; 2(3):297-8.
Score: 0.055
-
Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. Am Soc Clin Oncol Educ Book. 2015; e75-80.
Score: 0.050
-
American Society of Clinical Oncology policy statement on medicaid reform. J Clin Oncol. 2014 Dec 20; 32(36):4162-7.
Score: 0.050
-
Payment for oncolytics in the United States: a history of buy and bill and proposals for reform. J Oncol Pract. 2014 Nov; 10(6):357-62.
Score: 0.050
-
The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Res. 2014 Sep; 34(9):5043-50.
Score: 0.049
-
Achieving a deeper understanding of the implemented provisions of the Affordable Care Act. Am Soc Clin Oncol Educ Book. 2014; e472-7.
Score: 0.047
-
Achieving health equity in colorectal cancer: a call to action. Am Soc Clin Oncol Educ Book. 2013; 169-73.
Score: 0.044
-
Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90.
Score: 0.040
-
Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006 May 10; 24(14):2179-87.
Score: 0.028
-
Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005 Jul; 89(4):771-93.
Score: 0.026
-
Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
Score: 0.025
-
Evaluating the Addition of Clinical and Staging Data to Improve the Pricing Methodology of the Oncology Care Model. JCO Oncol Pract. 2022 11; 18(11):e1899-e1907.
Score: 0.022
-
Oncology alternative payment models: lessons from commercial insurance. Am J Manag Care. 2022 03; 28(3):98-100.
Score: 0.021
-
Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer. 2020 01 15; 126(2):281-292.
Score: 0.018
-
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631.
Score: 0.017
-
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.
Score: 0.017
-
The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. J Oncol Pract. 2018 07; 14(7):e412-e420.
Score: 0.016
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
Score: 0.015
-
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34.
Score: 0.014
-
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):957-66.
Score: 0.013
-
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77.
Score: 0.013
-
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
Score: 0.011
-
Infused chemotherapy use in the elderly after patent expiration. Am J Manag Care. 2012 May 01; 18(5):e173-8.
Score: 0.010
-
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 01; 29(28):3816-24.
Score: 0.010